SecBot SecBot
Insider Cluster (2 insiders) ·Filed Jul 2, 2026

ORMP

ORAMED PHARMACEUTICALS INC.
NEUTRAL
Impact 4/10
Horizondays Processed4mo ago
Insider cluster: 2 insiders, $942K total
Actionable Insight • Neutral

Insider selling at this scale is notable but not alarming for a $189M biotech. Watch for any upcoming corporate events (e.g., clinical data, partnership announcements) that may have motivated the trades. The lack of 10b5-1 plan disclosure reduces the signal's reliability.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$4.60
T+0 close · Jul 2, 2026 · via day close
Latest settled
+3.26%
T+60 · $4.75
Vs SPY
−0.31%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 6 $4.60entry
  2. T+1 · 4mo ago −0.65%α −1.52% · $4.57
  3. T+5 · 4mo ago −9.13%α −10.06% · $4.18
  4. T+20 · 4mo ago −10.43%α −10.02% · $4.12
  5. T+60 · 7w ago +3.26%α −0.31% · $4.75
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

COO/CBO Joshua Hexter and CFO Avraham Gabay collectively sold $942K in open-market shares on July 1, 2026, representing ~0.5% of Oramed's $189M market cap. The sales are moderate in size and involve two senior officers, but insider selling is a weak directional signal per academic literature, especially without evidence of 10b5-1 plans or a clear blackout context.

Key Financial Metrics

Direction
selling
Total Value
$942.0K
Insiders
2

Key Facts

  • Two C-suite insiders (COO/CBO and CFO) sold shares on July 1, 2026
  • Total open-market sales: $942,000 at ~$4.46-$4.51 per share
  • Sales represent ~0.5% of Oramed's $189M market cap
  • Hexter also exercised derivatives on July 2 (non-cash events)
  • Analyst consensus is bearish: 0% bullish, mostly hold/sell/strong sell ratings

Financial Impact

$942K in insider selling, about 0.5% of market cap

insider holdings reductionfloat increase from exercised options

Risk Factors

  • Additional insider selling could pressure shares
  • Bearish analyst consensus may amplify negative sentiment

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ORMP-1783026099934

Track record

4 reports on ORMP

Performance horizon
Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $4.03 Now $3.90 −3.23% settles Dec 15
  2. Oct 2, 20266w ago Insider Cluster Neutral 3/10 Entry $4.55 to $4.11 Now $3.90 −14.29% ▼ −9.67% −7.20% vs SPY
  3. Jul 2, 202619w ago Insider Cluster Neutral 4/10 Viewing Entry $4.60 to $4.12 Now $3.90 −15.22% ▼ −10.43% −10.02% vs SPY
  4. Jun 30, 202619w ago 8-K Mixed 5/10 Entry $4.61 to $3.97 Now $3.90 −15.40% ▼ −13.88% −11.70% vs SPY
Showing 4 of 4

US Market Status

Market Closed · Opens in 9h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 2, 2026